Be part of the knowledge.™

Oncology and Hematology

966

LikeLikedUnlike

151-165 of 285

Defining the Standard of Care and Optimal Sequencing in BRAF-Mutant mCRC: Second Line and Beyond
MinuteCE®
Defining the Standard of Care and Optimal Sequencing in BRAF-Mutant mCRC: Second Line and Beyond
- Fortunato Ciardiello, MD, PhD
  Peer
- Jenny Seligmann, MBChB, PhD
  Peer
1.00 program credits
Proactive Adverse Effect Management in mCRC: Improving Tolerability to Optimize Patient Outcomes
MinuteCE®
Proactive Adverse Effect Management in mCRC: Improving Tolerability to Optimize Patient Outcomes
- Fortunato Ciardiello, MD, PhD
  Peer
- Jenny Seligmann, MBChB, PhD
  Peer
1.00 program credits
ICI Combination Regimens for First-Line Treatment of Metastatic ESCC
MinuteCE®
ICI Combination Regimens for First-Line Treatment of Metastatic ESCC
- Harry Yoon, MD
  Peer
- Jaffer Ajani, MD
  Peer
0.75 program credits
Strategies for Navigating First-Line Treatment Selection in Metastatic ESCC
MinuteCE®
Strategies for Navigating First-Line Treatment Selection in Metastatic ESCC
- Harry Yoon, MD
  Peer
- Jaffer Ajani, MD
  Peer
0.75 program credits
Tailoring First-Line Regimens: Patient-Centric Selection in Metastatic ESCC
MinuteCE®
Tailoring First-Line Regimens: Patient-Centric Selection in Metastatic ESCC
- Harry Yoon, MD
  Peer
- Jaffer Ajani, MD
  Peer
0.75 program credits
The Impact of First-Line Treatment on Subsequent Treatment Options for Metastatic ESCC
MinuteCE®
The Impact of First-Line Treatment on Subsequent Treatment Options for Metastatic ESCC
- Harry Yoon, MD
  Peer
- Jaffer Ajani, MD
  Peer
0.75 program credits
advertisement
Case Consult: Adverse Effect Monitoring, Management, and Mitigation During Targeted Therapy for BRAF-Mutant mCRC
MinuteCE®
Case Consult: Adverse Effect Monitoring, Management, and Mitigation During Targeted Therapy for BRAF-Mutant mCRC
- Fortunato Ciardiello, MD, PhD
  Peer
- Jenny Seligmann, MBChB, PhD
  Peer
1.00 program credits
Second-Line Solutions in Metastatic TNBC: ADC Selection, Sequencing, and Safety
CME/CE
Second-Line Solutions in Metastatic TNBC: ADC Selection, Sequencing, and Safety
- Aditya Bardia, MD
  Peer
- Tiffany Traina, MD, FASCO
  Peer
0.25 credits
MinuteCE®
The Pathologist Perspective: Identifying Systemic Mastocytosis in the Community
- Nathan A. Boggs, MD
  Peer
- Tracy George, MD
  Peer
- Lindsay Rein, MD
  Peer
0.50 credits 4 episodes
MinuteCE®
Optimizing Ovarian Function Suppression in Hormone Receptor-Positive Breast Cancer: Best Practices for the Community Clinician
- Sandra Swain, MD
  Peer
- Virginia Kaklamani, MD
  Peer
0.50 credits 4 episodes
Differential Diagnosis of Indolent Systemic Mastocytosis
MinuteCE®
Differential Diagnosis of Indolent Systemic Mastocytosis
- Nathan A. Boggs, MD
  Peer
- Tracy George, MD
  Peer
- Lindsay Rein, MD
  Peer
0.50 program credits
Is it Nonresponsive/Progressive ISM?
MinuteCE®
Is it Nonresponsive/Progressive ISM?
- Nathan A. Boggs, MD
  Peer
- Tracy George, MD
  Peer
- Lindsay Rein, MD
  Peer
0.50 program credits
advertisement
Diagnosis and Treatment of Systemic Mastocytosis With an Associated Hematologic Neoplasm
MinuteCE®
Diagnosis and Treatment of Systemic Mastocytosis With an Associated Hematologic Neoplasm
- Nathan A. Boggs, MD
  Peer
- Tracy George, MD
  Peer
- Lindsay Rein, MD
  Peer
0.50 program credits
Accurate Diagnosis and Management of Hereditary Alpha Tryptasemia
MinuteCE®
Accurate Diagnosis and Management of Hereditary Alpha Tryptasemia
- Nathan A. Boggs, MD
  Peer
- Tracy George, MD
  Peer
- Lindsay Rein, MD
  Peer
0.50 program credits
Recent Updates on Ovarian Function Suppression in Premenopausal HR+ Early-Stage Breast Cancer
MinuteCE®
Recent Updates on Ovarian Function Suppression in Premenopausal HR+ Early-Stage Breast Cancer
- Sandra Swain, MD
  Peer
- Virginia Kaklamani, MD
  Peer
0.50 program credits

Program Chapters

Segment Chapters

Playlist:

Recommended